Core Viewpoint - A class-action lawsuit has been filed against James Hardie Industries plc, alleging securities fraud related to misleading information about inventory levels and customer demand in its North American segment [1][2]. Group 1: Lawsuit Details - The lawsuit, titled Laborers' District Council & Contractors' Pension Fund of Ohio v. James Hardie Industries PLC., covers a class period from May 20, 2025, to August 18, 2025, and seeks damages for violations of the Securities Exchange Act of 1934 [2][3]. - The plaintiffs claim that James Hardie's North America Fiber Cement segment, which accounts for approximately 80% of total earnings, was misrepresented by management despite signs of inventory destocking [3][4]. Group 2: Allegations of Misrepresentation - Executives allegedly made false statements around May 20 and 21, 2025, claiming robust customer demand while denying any inventory destocking [4][5]. - The complaint suggests that sales were artificially inflated due to "inventory loading by channel partners," indicating potential fraudulent practices [4][5]. Group 3: Impact of Disclosure - On August 19, 2025, James Hardie disclosed a 12% decline in sales for its North America Fiber Cement division, attributing it to the customer destocking previously denied [5][6]. - Following this disclosure, the company's stock price fell by over 34%, leading to significant losses for investors [6][7]. Group 4: Investigation and Next Steps - Hagens Berman is investigating the claims and is seeking information from investors who may have suffered losses or possess relevant knowledge [7][8]. - Whistleblowers with non-public information are encouraged to assist in the investigation, with potential rewards under the SEC Whistleblower program [9].

Lost Money on Inspire Medical Systems, Inc. (INSP)? Contact Levi & Korsinsky to Join Class Action Before January 5, 2026November 17, 2025 8:36 AM EST | Source: Levi & Korsinsky, LLPNew York, New York--(Newsfile Corp. - November 17, 2025) - If you suffered a loss on your Inspire Medical Systems, Inc. (NYSE: INSP) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/inspire-medical-systems-in ...

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/inspire-medical- ...

Core Viewpoint - Hormel Foods Corporation is under investigation for potential violations of securities laws, following a significant drop in share price due to recent negative disclosures regarding earnings and management changes [2]. Company Summary - The investigation by the Schall Law Firm focuses on whether Hormel issued false or misleading statements and failed to disclose critical information to investors [2]. - A Wall Street Journal article published on October 29, 2025, reported that Hormel cut its earnings forecast due to price pressures, bird flu, and a fire at its Arkansas peanut butter production facility, leading to a 9.1% decline in share price on the same day [2]. Legal Context - The Schall Law Firm is encouraging shareholders who have suffered losses to participate in the investigation and discuss their rights [3].

Core Viewpoint - Grabar Law Office is investigating claims on behalf of shareholders of Fluor Corporation regarding potential breaches of fiduciary duties by certain officers and directors [1] Group 1: Investigation Details - The investigation is focused on whether Fluor Corporation's officers made materially false and misleading statements and failed to disclose adverse facts about the company's business and operations [3] - Allegations include that costs for specific projects were increasing due to subcontractor errors, price hikes, and scheduling delays, which negatively impacted the company's financial results [3] - The investigation suggests that Fluor's financial guidance for FY 2025 was unreliable, and the effectiveness of its risk mitigation strategies was overstated [3] Group 2: Shareholder Actions - Shareholders who purchased Fluor Corporation shares before February 18, 2025, and still hold them can seek corporate reforms and the return of funds at no cost [2][4] - Interested shareholders are encouraged to contact Grabar Law Office for more information on the investigation and potential actions [2][4]

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit for securities fraud following a significant stock drop attributed to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - A class action lawsuit has been filed against Inspire Medical Systems and certain senior executives, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until January 5, 2026, to request to lead the case in the U.S. District Court for the District of Minnesota [3]. Group 2: Company Background - Inspire Medical Systems develops an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire assured investors of a timely launch for Inspire V, but failed to prepare clinicians and payors adequately, leading to delays and weak demand due to excess inventory of older devices [5][6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price dropped by $42.04, or more than 32%, from $129.95 to $87.91 per share [8].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - James Hardie Industries plc is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the United States and Canada [4]. Allegations and Misrepresentation - During the relevant period, James Hardie claimed that its North American fiber cement segment showed "inherent strength" and "underlying momentum," while in reality, sales were inflated due to inventory loading by channel partners, indicating fraudulent channel stuffing rather than genuine customer demand [5]. Stock Performance and Impact - On August 19, 2025, James Hardie disclosed a 12% decline in North American fiber cement sales, attributed to destocking efforts by customers. This revelation led to a stock price drop of $9.79 per share, over 34%, from $28.43 to $18.64 within a day [6].

Core Insights - Kirby McInerney LLP is investigating potential claims against Ardent Health, Inc. regarding possible violations of federal securities laws or unlawful business practices [1][3] Financial Results - On November 12, 2025, Ardent announced its third-quarter financial results, revealing a $43 million reduction in revenue due to changes in accounting estimates related to accounts receivable [3] - The company also disclosed a $54 million increase in professional liability reserves for claims in New Mexico [3] - Following this announcement, Ardent's share price fell by $4.75, approximately 33.8%, from $14.05 to $9.30 [3]

Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. alleging securities fraud that affected investors between January 8, 2024, and September 17, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, without approval from the U.S. Food and Drug Administration [2]. - It is alleged that these design changes compromised the reliability of the G6 and G7 devices, posing a significant health risk to users who depend on accurate glucose readings [2]. - The complaint asserts that the enhancements claimed for the G7, including its reliability, accuracy, and functionality, were overstated by the defendants [2]. - Defendants are accused of downplaying the severity of the issues and health risks associated with the altered G7 devices [2]. - The lawsuit suggests that these actions exposed DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [2]. - As a result, the public statements made by the defendants were deemed materially false and misleading throughout the relevant period [2]. Group 2: Next Steps for Investors - Investors who suffered losses in DexCom, Inc. during the specified timeframe have until December 26, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has a strong track record in high-stakes securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against Fiserv, Inc. for allegedly violating federal securities laws by issuing false and misleading statements regarding its business and financial health, leading to a significant decline in stock price and market value [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Fiserv's management, including the CEO and CFO, overstated growth potential and provided unrealistic financial guidance between July 23 and October 28, 2025 [2]. - Following a drastic cut in forecasts and poor third-quarter results, Fiserv's stock price dropped by 44%, resulting in an approximate loss of $30 billion in market value [2]. - Investors were reportedly misled by positive statements about the company's strategic direction, which later proved to be unattainable, necessitating a major overhaul in leadership and business strategy [2]. Group 2: Legal Proceedings - The lawsuit is filed in the Eastern District of Wisconsin under the case name Lombard v. Fiserv, Inc., et al., and is on behalf of all investors who purchased Fiserv stock during the specified class period [3]. - Investors who acquired Fiserv stock during the class period may seek to be appointed as lead plaintiffs, with a deadline for such motions set for January 5, 2026 [4]. - Participation as a lead plaintiff is not required to share in any potential recovery from the lawsuit [5].